Importance of Non-Randomized Controlled Trials_Chinese Journal of Evidence-Based Medicine

Authors：

WU Hongtao , ZHOU Dong , HE Li

Department of Neurology; West China Hospital of Sichuan University; Chengdu 610041; China;

Corresponding author：

Keywords：

Non-randomized controlled trials; Multiple sclerosis

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Randomized controlled trials (RCTs) are the gold standard for the design of clinical trials. Because of some practical difficulties, more and more researchers think that the appropriate use of non-randomized controlled trials may make up for the weakness of RCT and will achieve the same research purpose. Therefore, non-RCTs are also very important. Taking studies on multiple sclerosis for example, this article briefly introduces the significance of non-randomized contolled trials.

Citation： WU Hongtao,ZHOU Dong,HE Li. Importance of Non-Randomized Controlled Trials. Chinese Journal of Evidence-Based Medicine, 2004, 04(8): 570-572. doi: Copy

1.	［1］Byar DP, Simon RM, Friedewald WT. Randomized clinical trials: perspectives on some recent ideas [J]. N Engl J Med,1976; 295(5): 74-80.
2.	［2］Wang JY. Editor-in-chief. Evidence-based medicine and its clinical practice [ M ]. Shanghai: Science and Technology Publishing House. 2002. 279.
3.	王吉耀主编.循证医学与临床实践[M],上海:科学出版社.2002.279.
4.	［3］Lublin FD, Reingold SC. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials m MS [J]. Ann Neurol, 2001 ;49(5): 677 -681.
5.	［4］Sacks H, Chalmers TC, Smith H Jr. Randomized versus historical controls for clinical trials [J]. Am J Med, 1982;72(3): 233 - 240.
6.	［5］Pocock SJ, Elbourne DR. Randomized trials or observational tribulations [J ] ? N Engl J Med, 2000; 342 ( 25 ): 1 907 -1909.
7.	［6］Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Choosing between randomized and non-randomised studies : a systematic review [ J ]. Health Technol Assess, 1998;2(13): i-iv,1 -124.
8.	［7］Concato J, Shah N, Horwitz RI. Randomized, controlled trials , observational studies, and the hierarchy of research designs [J]. N Engl J Med, 2000; 342(25): 1 887-1 892.
9.	［8］Temple R, Ellenberg SS. Placebo-controlled trials and activecontrol trials in the evaluation of new treatment. Part 1: Ethical and Scientific Issues[J]. Ann lntern Med, 2000; 133(9):455 - 463.
10.	［9］PRISMS ( Prevention of R elapses and Disability by Interferonbeta-la Subcataneously in MS ) Study Group. PRISMS-4:Long-term efficacy of interferon-beta-1 a in relapsing MS [J].Neurology, 2001; 56(3): 1 628-1 636.
11.	［10］Goodkin DE, Reingold S, Sibley W. Guidelines for clinical trials of new therapeutic agents in MS: reporting extended results from phase 3 clinical trials [J]. Ann Neurol,1999; 46(6): 132 -134.

1. ［1］Byar DP, Simon RM, Friedewald WT. Randomized clinical trials: perspectives on some recent ideas [J]. N Engl J Med,1976; 295(5): 74-80.
2. ［2］Wang JY. Editor-in-chief. Evidence-based medicine and its clinical practice [ M ]. Shanghai: Science and Technology Publishing House. 2002. 279.
3. 王吉耀主编.循证医学与临床实践[M],上海:科学出版社.2002.279.
4. ［3］Lublin FD, Reingold SC. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials m MS [J]. Ann Neurol, 2001 ;49(5): 677 -681.
5. ［4］Sacks H, Chalmers TC, Smith H Jr. Randomized versus historical controls for clinical trials [J]. Am J Med, 1982;72(3): 233 - 240.
6. ［5］Pocock SJ, Elbourne DR. Randomized trials or observational tribulations [J ] ? N Engl J Med, 2000; 342 ( 25 ): 1 907 -1909.
7. ［6］Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Choosing between randomized and non-randomised studies : a systematic review [ J ]. Health Technol Assess, 1998;2(13): i-iv,1 -124.
8. ［7］Concato J, Shah N, Horwitz RI. Randomized, controlled trials , observational studies, and the hierarchy of research designs [J]. N Engl J Med, 2000; 342(25): 1 887-1 892.
9. ［8］Temple R, Ellenberg SS. Placebo-controlled trials and activecontrol trials in the evaluation of new treatment. Part 1: Ethical and Scientific Issues[J]. Ann lntern Med, 2000; 133(9):455 - 463.
10. ［9］PRISMS ( Prevention of R elapses and Disability by Interferonbeta-la Subcataneously in MS ) Study Group. PRISMS-4:Long-term efficacy of interferon-beta-1 a in relapsing MS [J].Neurology, 2001; 56(3): 1 628-1 636.
11. ［10］Goodkin DE, Reingold S, Sibley W. Guidelines for clinical trials of new therapeutic agents in MS: reporting extended results from phase 3 clinical trials [J]. Ann Neurol,1999; 46(6): 132 -134.

Chinese Journal of Evidence-Based Medicine

Importance of Non-Randomized Controlled Trials

Abstract Full text Figures/Tables Video References Cited by

Format

Content